ABSTRACT
BACKGROUND: Interleukin-1 is an important pro-inflammatory cytokine that has been documented in the regulation of bone inflammation and bone remodeling. A previous study has demonstrated that interleukin-1α can induce apoptosis while inhibiting osteoblast differentiation in MC3T3-E1 cells. OBJECTIVE: To investigate the role and mechanism of interleukin-1α on osteoclast activation and bone loss in mice. METHODS: (1) Cell test: RAW264.7 cells were either treated with interleukin-1α alone or with receptor activator of nuclear factor-κB ligand (RANKL) for 1 and 4 days. Cell viability was tested by cell counting kit-8 assay. The number of multinuclear osteoclasts was detected by tartrate resistant acid phosphatase assay. The mRNA and protein levels of osteoclast-specific genes and genes related to nuclear factor-κB pathway and Wnt/β-catenin pathway were tested by real-time fluorescence quantitative PCR, immunofluorescence staining or western blot. Bone marrow-derived macrophages were either treated with interleukin-1α alone or with RANKL and macrophage colony-stimulating factor for 7 days. The number of multinuclear osteoclasts was detected by tartrate resistant acid phosphatase assay. The protein levels of osteoclast-specific genes were tested by western blot. (2) Animal test: Twenty-four male C57BL/6J mice (6-8 weeks old) were assigned into two groups at random: control group and test group. Mice were subsequently treated with interleukin-1α solution or PBS by intraperitoneal injection twice a week for 5 weeks. Bone tissues from the femurs were performed with micro-computed tomography analysis and hematoxylin-eosin staining, tartrate resistant acid phosphatase, and immunofluorescence analysis. RESULTS AND CONCLUSION: Cell test: Interleukin-1α alone significantly increased RAW264.7 cell proliferation, but stimulated cell differentiation into osteoclasts in combination with RANKL (P < 0.05). Interleukin-1α significantly increased the expression of osteoclast-related markers and the number of tartrate resistant acid phosphatase-positive multinuclear cells in RAW264.7 cells and bone marrow-derived macrophages in the existence of RANKL or RANKL+macrophage colony-stimulating factor (both P < 0.05). Interleukin-1α was found to significantly enhance the nuclear factor-κB and Wnt/beta-catenin signaling in RAW264.7 cells (P < 0.05). Blocking of nuclear factor-κB or Wnt3 signaling not only reversed the activation of nuclear factor-κB and Wnt3 signaling but also weakened the enhanced expression of osteoclast-specific genes induced by interleukin-1α in RAW264.7 cells (P < 0.05). Animal test: interleukin-1α induced bone loss in mice while also upregulating the expression of osteoclast-specific markers, RANK, TRAF6 and p65, and Wnt3 in vivo (P < 0.05). The findings indicate that interleukin-1α can induce osteoclast activation and bone loss by promoting the nuclear factor-κB and Wnt signaling pathways.
ABSTRACT
BACKGROUND: Defective dentition is a common oral disease, if it is not treated in time, there will be adverse effects such as tilting of the adjacent teeth and elongation of the jaws, causing occlusal disorder and interference, which will seriously affect the later repair. Especially in the diabetic patients with dentition loss, the impacts of diabetes on the occlusal elongation of the jaw teeth, and how osteonectin changes in this process, are still unclear. OBJECTIVE: To investigate the effect of diabetes on tooth occlusion and elongation in mice by establishing a model of the occlusion of the jaws in diabetic mice. METHODS: A diabetic model was established by intraperitoneal injection of streptozotocin in C57 BL/6J mice (purchased from the Animal Experimental Center of Shanxi Medical University). The mice were intraperitoneally injected with sodium citrate buffer. Thirty mice with successful modeling and control mice were removed, and the three right maxillary molars were removed to establish an experimental model of the extensional movement of the maxillary teeth. After 0, 3, 6, 9 and 12 days, the right jaw was taken. The bone mineral density was measured by micro-CT. The number of osteoclasts was counted by tartrate resistant acid phosphatase staining. The expression level of osteonectin was detected by RT-qPCR. The study was approved by the Ethical Committee of Shanxi Medical University. RESULTS AND CONCLUSION: (1) With the time increasing, the bone mineral density of the right mandible in the two groups was gradually increased. The bone mineral density in the diabetic group was significantly lower than that in the control group at 3, 6, 9 and 12 days after surgery (P < 0.05). (2) With the time increasing, the number of osteoclasts in the right mandible of both groups was gradually increased. The number of osteoclasts in the diabetic group was significantly lower than that in the control group at 3, 6, 9 and 12 days after surgery (P < 0.05). (3) The expression level of osteonectin mRNA in the right mandible of both groups was gradually increased. The expression level of osteonectin mRNA in the diabetic group was significantly higher than that in the control group at 0, 3,6, 9 and 12 days after surgery (P< 0.05). (4) These results indicate that diabetes can reduce the bone construction ability during the extensional movement and promote osteonectin mRNA expression.
ABSTRACT
Objective The aim of this study was to investigate the effect of Ca2+ /calmodulin - dependent kinase II (CaMKII)γ RNA interference on the expression of nuclear factor of activated T-cells cytoplasmic 1(NFATc1),tyrosine kinase(c-Src)and tartrate resistant acid phosphatase(TRAP)genes,and its role and molecular mechanism in osteoclast differentiation. Methods The CaMKII γ RNA interference vector was constructed by lentivirus and transfected into RAW264. 7 cells. The experiment was di-vided into three groups:A,B and C,which were the control group,negative vector group and interference vector group. After transfec-tion for 12 hours,osteoclasts induced by 50 ng/mL RANKL and the cells were harvested after induction for 5 days. Real-time quanti-tative PCR,Western blot and immunofluorescence were used to detect the expression of NFATc1,TRAP and c-Src genes in three groups. Results The mRNA levels of NFATc1,TRAP and c-Src in the group C decreased by 49. 86% ,43. 65% and 53. 57% ,re-spectively(P<0. 001),and the protein levels decreased by 54. 22% ,46. 75% and 45. 86% ,respectively(P<0. 001). There was no significant difference between the A and the B groups(P>0. 05). The fluorescence intensity of the above genes in the group C was significantly weaker than that in the A and B groups,and the formation of osteoclasts was significantly less than that in the A and B groups. Conclusion CaMKIIγ RNA interference significantly inhibited the expression of NFATc1,TRAP and c-Src genes,sugges-ting that CaMKIIγ plays a key regulatory role in osteoclast differentiation.
ABSTRACT
Objective:To study the expression profiles and the role of Ca2+/calmodulin-dependent protein kinase Ⅱγ (CaMKⅡγ) during osteoclast differentiation.Methods:Mouse RAW264.7 cells were induced for osteoclastogenesis with 50 ng/mL receptor activator of nuclear factor-κB ligand (RANKL) and the cells were harvested at 0,1,3 and 5 days after induction.Tartrate-resistant acid phosphotase staining was performed to verify osteoclasts formation.RT-PCR,Western blot and immunofluorescent cytochemistry were used to detect the CaMKⅡγ gene expression during osteoclastogenesis.Results:The osteodasts were formed at day 3 under RANKL induction and more osteoclasts were observed at day 5.At day 0,1,3 and 5,the relative level of CaMKⅡγ mRNA were (1.067±0.179),(1.840±0.070),(9.493±0.453) and (30.767±0.573),respectively,and the relative protein level were (0.454±0.065),(0.613±0.021),(0.858±0.019) and (0.980±0.023),respectively.CaMKⅡγ expression was increased in a time-dependent manner except relative protein level at day 1 (P＜0.01),which showed no significant difference at day 0 (P＞0.05).Immunofluorescence assay showed that CaMKⅡγ protein was also increased with differentiation of osteoclasts.Conclusion:The CaMKⅡγ expression was increased in a time-depended manner during osteoclast differentiation and it might play a vital role during osteoclastogenesis.
ABSTRACT
Objective To observe the clinical effect of the Bushen-Qiangjin capsule and calcium D in the treatment of aromatase inhibitors-associated bone loss (AIBL) in breast cancer patients. Methods A total of 65 patients were randomized into a treatment group and a control group, 32 in the control group taking calcium D, and 33 in the treatment group taking calcium D and Bushen-Qiangjin capsule. After a 3-month treatment, the bone mineral density T (BMD), bone-specific alkaline phosphatase (BALP), bone gla protein (BGP) and tartrate resistant acid phosphatase (TrACP) of two groups were evaluated. Results The BMD increased significantly after treatment in both groups (P<0.05), and the therapeutic efficacy of the treatment group was better than of the control group (P<0.05). After treatment, the level of BALP (308.76 ± 10.99 U/L vs. 280.00 ± 7.44 U/L, t=8.170) and the BGP (42.21 ± 3.04 ng/ml vs. 34.38 ± 2.06 ng/ml, t=6.818) of the treatment group were significantly higher than those of the control group (P<0.01). The level of TrACP decreased significantly after treatment in both groups (P<0.05), and the TrACP (60.12 ± 4.58 U/L vs. 67.25±4.06 U/L, t=1.653) of treatment group was significantly lower than that of the control group (P<0.05). Conclusions The Bushen-Qiangjin capsule can produce a content efficacy in treating AIBL in breast cancer patients, improving the BMD and bone metabolism.
ABSTRACT
Objective To study the effect of zoledronate (ZOL) on Ca2+/calmodulin-dependent kinase Ⅱ δ (CaMK Ⅱ δ) and down-stream gene expressions during osteoclast differentiation.Methods Mouse osteoclast precursors RAW264.7 cells were divided into the control group and ZOL group.The cells in both groups were induced with 50μg/L receptor activator of nuclear factor kappa B ligand (RANKL) and were harvested on 5 d,while the cells in ZOL group were also simultaneously treated with 1 × 10-6 mol/L ZOL for 2 d.Five days later,the cells were harvested and examined osteoclastogenesis,as well as gene expressions of CaMK Ⅱ δ,nuclear factor of activated T-cells cytoplasmic 1 (NFATc1),tartrate-resistant acid phosphatase (TRAP) and cell-sarcoma receptor coactivator (c-Src).Results The number of TRAP positive multinuclear osteoclasts,number and size of dentin absorption lacunae and area in the ZOL group were (20.0±3.2),(18.0±4.2) and (6 335.3± 1 043.2)μm2 respectively,which were significantly lower than (36.0 ± 8.4),(37.2 ± 5.0) and (11 636.2 ± 3 661.1) μm2 in the control group and decreased by 44.4 ％,51.6 ％ and 45.6 ％ respectively (P＜0.01).ZOL also significantly inhibited the gene expressions of CaMK Ⅱ δ,NFATc1,TRAP and c-Src,and the mRNA levels of these genes were decreased by 44.1％,49.0％,53.8％ and 49.6％ respectively,the protein level were decreased by 43.5 ％,32.2 ％,45.5 ％ and 48.0 ％ respectively.The immunofluorescent cytochemistry detection results showed the fluorescence intensity of CaMK Ⅱ δ,NFATc1,TRAP and c-Srcin in the ZOL group was significantly weakened when compared with the control group.Conclusion ZOL could significantly inhibit the osteoclast formation and bone absorption function,and down-regulates gene expressions of CaMK Ⅱ δ,NFATc1,TRAP and c-Src in osteoclast differentiation.
ABSTRACT
OBJECTIVES: This study aimed to investigate the correlation between bone mineral density (BMD) and the turnover rate [√(MoMf²+ MoMr²), multiple of median formation (MoMf) was calculated as bone-specific alkaline phosphatase (BAP) value/18.6 and multiple of median resorption (MoMr) as tartrate-resistant acid phosphatase 5b (TRACP-5b) value/463] and the balance (MoMf/MoMr) and to compare differences in therapeutic effects evoked by differences in previous treatments. METHODS: In 51 osteoporotic women treated with bisphosphonates (BPs) or selective estrogen receptor modulators (SERMs), BMD was measured at 0, 24, and 48 weeks after denosumab administration. The values of BAP and TRACP-5b were measured at 0, 4, 12, 24, 36, and 48 weeks. RESULTS: The turnover rate decreased at week 4 and decreased further at week 12. The balance indicated a relative predominantly formative state at week 4. This balance became higher in the SERM group than in the BP group at week 4. A correlation was observed between the rate of BMD change and turnover rate at weeks 0 and 4. CONCLUSIONS: It is necessary to evaluate the turnover rate and balance to determine the therapeutic effect of denosumab, which induces dissociation between the trends in the bone turnover markers. Turnover rate and balance during the early stages of denosumab treatment may be predictive factors of BMD. When switching from bone resorption inhibitors to denosumab, it was necessary to consider the beginning values that were affected by the previous treatment. The state of relative anabolism is greater at 4 weeks when the previous treatment involved SERMs rather than BPs.
Subject(s)
Female , Humans , Acid Phosphatase , Alkaline Phosphatase , Bone Density Conservation Agents , Bone Density , Bone Remodeling , Bone Resorption , Denosumab , Diphosphonates , Metabolism , Osteoporosis , Selective Estrogen Receptor Modulators , Therapeutic UsesABSTRACT
Objective To investigate the clinical and laboratory diagnosis in a rare case with dwarifsm and multisystem abnormalities. Methods Whole-exome sequencing was performed and data was processed using high-throughput data analysis pipeline. Genetic test result is veriifed by Sanger sequencing. Results This is a 14-year-old boy with short stature (the height is 132 cm) and autoimmune hemolytic anemia. He was treated with long-term oral prednisone. Head CT from other hospital found multiple calciifcations on both sides of the basal ganglia, two sides of the frontal lobe, and the left side of parietal lobe. Lateral spinal X-ray photography showed lfat in thoracolumbar vertebral body. Valgus was surgically corrected. He also has facial pigmentation spot and onychomycosis. Whole-exome sequencing combined with Sanger sequencing identiifed a known homozygous pathogenic mutation in ACP 5 genes (c. 643 G>A, p.G 215 R). Identiifcation of such a mutation results in the diagnosis of spondylo enchondrody splasia with immune dysregulation (SPENCDI). Conclusions Whole-exome sequencing is one of the effective methods for detection of rare disease, the SPENCDI case reported here is a good example of it.
ABSTRACT
[ ABSTRACT] AIM:To study the expression profiles and the role of Ca 2+/calmodulin-dependent kinase II delta ( CaMKIIδ) during osteoclast differentiation .METHODS:Mouse RAW264.7 cells were induced by receptor activator of nuclear factor κB ligand ( RANKL) at 50μg/L for osteoclastogenesis .Tartrate-resistant acid phosphatase ( TRAP) staining and bone resorption lacunae examination were performed to verify osteoclast formation .The expression of CaMKIIδat mR-NA and protein levels was also determined by immunofluorescent cytochemistry , RT-qPCR and Western blot at days 0, 1, 3 and 5.RESULTS:TRAP positive multinuclear cells with bone resorption function were formed after 5 d of induction. The mRNA levels of CaMKIIδdetected by RT-qPCR were 1.028 ±0.041, 2.478 ±0.087, 10.524 ±1.284 and 42.914 ± 2.667 at days 0, 1, 3 and 5, respectively, while the protein levels of CaMKIIδ detected by Western blot were 0.762, 0.963, 1.802 and 3.136, respectively.The changes of protein level were also verified by immunofluorescence cytochemis -try, in which the fluorescence intensity increased in a time-dependent manner (P<0.05).CONCLUSION:The expres-sion of CaMKIIδincreases with the differentiation of osteoclasts .CaMKIIδmay play a key role in the osteoclastogenesis .
ABSTRACT
STUDY DESIGN: Retrospective study. PURPOSE: We conducted a study to investigate the time course changes in bone metabolic markers after the administration of the anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody and to assess drug compliance among osteoporotic patients. OVERVIEW OF LITERATURE: The anti-RANKL antibody is expected to provide an improvement in those with a bone metabolism disorder. However there are only a few clinical reports available on the effect of treatment. METHODS: We included 40 post-menopausal osteoporotic patients who received the anti-RANKL antibody. To determine the time course changes in the bone metabolic markers, we measured the serum tartrate-resistant acid phosphatase 5b (TRACP 5b; a bone resorption marker) and the serum N-terminal propeptide of type 1 collagen (P1NP; a bone formation marker) levels prior to and 1 month after administrating the anti-RANKL antibody. To evaluable drug compliance, we assessed the dropout rate during treatment and at 6 months after treatment. RESULTS: The average TRACP 5b level significantly decreased from 574.8 mU/dL before treatment to 153.2 mU/dL 1 month after treatment (p0.05). As for drug compliance, we did not have any dropouts during the treatment or after 6 months (dropout rate: 0%). CONCLUSIONS: Our study suggests that anti-RANKL antibody treatment suppresses bone resorption and maintains bone formation.
Subject(s)
Humans , Acid Phosphatase , Bone Resorption , Collagen Type I , Compliance , Metabolism , Osteogenesis , Osteoporosis , Patient Dropouts , RANK Ligand , Retrospective StudiesABSTRACT
Objective To study the effects of parthenolide on osteoclast differentiation of RAW264. 7 cell induced by receptor activator of nuclear factor κB ligand (RANKL). Methods The mouse macrophage RAW264.7 cells induced by RANKL was used alone as the control group, different concentrations of par-thenolide (0.5, 1, 2 μmol/L) were added to culture the RAW264.7 cells. On the third, fifth and seventh day, the tartrate resistant acid phosphatase (TRAP) staining method was used to detect osteodast-like cells and the cell number was count;the contents of tartrate resistant acid phosphatase (TRAP5b) in the Culture supernatant of each groups were detected by enzyme linked immunosorbent assay (ELISA) and the expression of osteodast marker gene alcitonin receptor (CTR) and matrix metalloproteinase (MMP)-9 in each groups were detected by realtime-polymerase chain reaction (PCR) on the seventh day. We use Chi-square test and t test to test the differences between groups by SPSS 17.0. Results In different culture conditions, RANKL could always induce the RAW264.7 cell differentiate into mature osteoclasts. Compared with the control group at the same time control group, on the third, fifth and seventh day, he number of mature osteoclasts induced were obviously decreased in groups adding different concentration of PAR; the number of induced osteoclasts decreased along with the increase of parthenolide concentration, on the seventh day in 0.5, 1, 2 μmol/L concentration PAR groups, the number of mature osteoclasts compared with the control group were descended 36.3%, 40.8%, 49.3%(t=7.758, 8.742, 10.56;P<0.05);the contents of TRAP5b in the culture supernatant were consistent with the cell counting results on the seventh day (P<0.05). The expression of CTR and MMP-9 by TRAP positive osteoclasts decreased along with the increase of parthenolide concentration, and the 2 μmol/L group was the lowest. Compared with the control group, there were statistically significant differences with the different PAR concentration groups 0.5, 1, 2 μmol/L (P<0.05). Conclusion Parthenolide can inhibit RANKL induced RAW264.7 differentiation into osteoclast cells, and the inhibition is dose dependent.
ABSTRACT
Objective: To explore the effect of sika pilose antler type I collagen (SPC-I) on osteoclast and its molecular mechanism. Methods: The osteoclasts and osteoblasts were cultured by the induction method of whole bone marrow cells. The control (with full medium), osteoclasts (with HG-DMEM inducing medium), and SPC-I (2.5, 5, and 10 g/L) groups were set up. Except the control group, others were given the HG-DMEM inducing medium with each 40 ng/mL of both RANKL and macrophage colony-stimulating factor (M-CSF), then conditioned cultured for 7 d, every other 3 d to replace medium for the complement of the drug concentration. By HE and tartrate-resistant acid phosphatase (TRAP) stainings, the cell morphology was observed under inverted microscope. The TRAP activity was detected using spectrophotometer, the gene expression of TRAP, receptor activator of NF-κB (RANK), receptor activator of NF-κB lig and (RANKL), and osteoprotegerin (OPG) was measured by RT-PCR, and the RANK protein expression was detected by Western blotting. Results: Compared with the osteoclast group, SPC-I (5 and 10 g/L) groups could make TRAP positive cells and TRAP activity decreased, TRAP, RANK, and RANKL expression in gene level reduced, and RANK expression in protein level down-regulated also (P<0.01); Compared with the control group, SPC-I (2.5 and 10 g/L) could make the OPG expression in gene level increased and the RANKL/OPG ratio declined (P<0.01). The effect of 5 g/L SPC-I was the most significant (P<0.01). The effect of 2.5g/L SPC-I was not significant. Conclusion: SPC-I has the inhibitory effect on the osteoclast formation and differentiation; The effect of implementation is through RANKL/OPG signal transduction pathway to regulate the expression of TRAP and RANK genes.
ABSTRACT
Objective To investigate the effect of mechanical loading with different magnitudes on the proliferation, differentiation and activity of preosteoclasts and osteoclasts. Methods One group of RAW264.7 preosteoclastic cells cultured in osteoclast inductive medium were subjected to the cyclic tensile strain for three days, and then cultured for four days; the other group of RAW264.7 cells were induced in osteoclast inductive medium for four days to be osteoclasts, then subjected to the cyclic tensile strain for three days. Results Under the tensile strain at different magnitudes, the proliferation variations in two groups of RAW264.7 cells were approximately identical, but changes in the activities of tartrate-resistant acid phosphatage (TRAP) and numbers of TRAP-positive multinucleated cells (osteoclasts) in the two groups were significantly different. Under the moderate tensile strain (2 500 με), the reduction of TRAP activity and osteoclasts number were both the highest in the first group, and both the lowest in the second group. Conclusions The influence of different tensile strain on osteoclast differentiation and osteoclastic activity of preosteoclasts in early differentiation is different to that of the preosteoclasts already differentiated into osteoclasts.
ABSTRACT
O objetivo deste trabalho foi estudar o padrão de variação da atividade sérica da fosfatase alcalina total (tALP), da isoenzima óssea da fosfatase alcalina (BALP) e da fosfatase ácida resistente ao tartarato (TRAP), assim como a variação da concentração dos minerais séricos durante o processo de cicatrização de fraturas ósseas no cão. A variação sérica destes marcadores do metabolismo ósseo foi avaliada em nove cães com fraturas diafisárias fechadas de ossos longos, submetidas a tratamento cirúrgico para osteosíntese. Durante o período pós-operatório, sete animais evoluíram no sentido de uma normal união óssea, sendo que dois deles desenvolveram um processo de não união óssea. Foram observados, relativamente à BALP, valores de actividade sérica mais elevados e com diferença estatística (P<0,05) no grupo de animais que evoluiu no sentido de uma normal união óssea, comparativamente ao grupo de animais que evoluiu no sentido do processo de não união. No grupo de animais que evoluiu para a completa união óssea foram, adicionalmente, observados valores diminuidos (P<0,05) da atividade sérica da TRAP, até ao dia 60 do período pós-operatório seguido de uma elevação estatisticamente significativa após este período. Em conclusão, os biomarcadores do metabolismo ósseo poderão vir a constituir um método auxiliar de diagnóstico na monitorização do processo de cicatrização de fracturas ósseas, possibilitando, a detecção precoce de complicações pós-operatórias.
Subject(s)
Animals , Acid Phosphatase , Alkaline Phosphatase , Dogs , Fractures, Bone/veterinary , Tartrates , Fracture Fixation, Internal , Fracture Healing , Bone and Bones/metabolism , Postoperative PeriodABSTRACT
Objective To detect the serum level of tartrate-resistant acid phosphatase 5b (TRACP5b) in patients with rheumatoid arthritis (RA) before and after infliximab treatment and analyze the relevance between TRACP-5b and activity indexes of RA.The effect of different medicines on bony erosion in RA and its possible mechanism were explored.Methods Patients were divided into two groups:16 patients were treated with inffiximab for 24 weeks (group 1 ),25 patients were treated with MTX for 24 weeks (group 2).The core indicators of RA activity were evaluated.Ranked test,grouped design and matched t test was used to examine the quantity data between groups,while numerate data was analyzed with qui-square test.Correlation between data was tested by Spearmen's and Pearson's tests.RestltsThe levels of TRACP-5b in patients with X-ray stagesⅠ ,Ⅱ ,Ⅲ ,Ⅳ were elevated at the baseline.The levels of TRACP-5b in phase Ⅲ and Ⅳ were [(3.34±1.07) U/L] and[(4.05±0.25) U/L] respectively,higher (P＜0.05) than those in phase Ⅰ[(1.69±0.48) U/L].At week 0,week 12,and week 24,the serum levels of TRACP-5b in group 1 were(3.07±1.32),(2.72±1.18),(2.16±1.09) U/L respectively,while the levels in week 12,and 24 were significantly lower than those of week 0(P＜0.05).A significant decrease of serum TRACP-5b level in group 1[(2.16±1.09 ) U/L]when compared to group two[ (3.05±0.93) U/L] after 24 weeks.TRACP=5b level was positively correlated with the course of disease (r=0.313,P=0.043 ),HAQ(r=0.443,P=0.007).Conclusion Infliximab can reduce TRACP-5b level in RA and inhibit inflammatory bone loss.TRACP-5b can be used to evaluate the efficacy of biological agents in treating RA.
ABSTRACT
The aim of this study is to examine the change of the osteoclastic activity in the surrounding bone with or without tooth movement after corticotomy by histologic study. Eighteen male Sprague Dawley rats with an average body weight of 300 g(range 250-350 g) were used. The rats were divided into three groups of six animals. They were operated corticotomy-assisted tooth movement and killed after 1 week, 2 weeks, and 3 weeks after tooth movement. Corticotomy was done in the surrounding of the both upper first molar. A split mouth design was used by referring to the contralateral side as control. After flap suturing, the upper left first molar was moved anteriorly by closed coil spring. The force applied was 1 N. The average of tooth movement of the 1 week group was 0.24+/-0.09 mm, 0.20+/-0.26 mm in 2 weeks group and 0.41+/-0.39 mm in 3 weeks group, respectively. The difference between the 1 week and the 2 weeks groups was very small to compare with the 3 weeks group. In the treatment group, the average numbers of cells that positively reacted to TRAP were 14.5 in the 1 week group, 12.0 in the 2 weeks group, and 6.0 in the 3 weeks group. In the control group, the numbers were 8.3 in the 1 week group, 12.8 in the 2 week group, and 1.5 in the 3 week group, respectively. The amount of tooth movement of the 3 week group was about twice as large as those of the 1 week and 2 week groups. From the standpoint of histology, the average number of cells that positively reacted to TRAP was initially larger in the treatment group than in the control group, similar in both group in 2 weeks, and became less in the treatment group in 3 weeks. Additionally, in the control group, their activity of osteoclast was higher in 2 weeks than in 1 week, and decreased rapidly in 3 weeks.
Subject(s)
Animals , Humans , Male , Rats , Body Weight , Molar , Mouth , Osteoclasts , Rats, Sprague-Dawley , Tooth Movement Techniques , ToothABSTRACT
Objective To investigate the osteoclast′s function levels in infants and toddlers and the relationship between the osteoclast function and sex,age,body length,body weight and body mass index(BMI).Methods Sixty-eight children(37 boys and 31 girls,aged from 1 to 36 months) were studied.All of the children were in good health.These children were divided as infants group and toddlers group according to their age.Just before the samples were collected,the children′s body weight,body length were measured and the BMI were calculated.Two biochemical markers,such as serum tartrate-resistant acid phosphatase 5b(TRAP5b) and urine deoxypyridinoline(DPD) were measured.Results The difference of serum TRAP5b concentration between infants and toddlers was significant at the level of P
ABSTRACT
Objective To study the effect of estrogen,recombine human growth hormone and their combinations on residual ridge reduction in osteoporotic rats.Methods Animal models were established by ovariectomy and exodontia on left partial maxillary,then were devided into osteoporosis group and treatment groups;treatment groups were given estrogen and recombine human growth hormone medicial alone and their recombinations.After treatment for 4 and 8 weeks with drugs,the effects of estrogen and recombine human growth hormone on the serum tartrate-resistant acid phosphatase level and bone histomorphometry changes in maxillary were observed in each group. Results ① The serum tartrate-resistant acid phosphatase level was obvionsly lower in ERT group and Er-HGH group than in OP group(P
ABSTRACT
AIM :To investigate the impact of alendronate on bone resorption of normal and ovariectomized rats at the bone-screw interface through radiographic and histologic findings.METHODS :Thirty-two female Wister rats with a mean body weight of 332 g(287-351 g)were divided into four groups at random.Rats in group C and D were ovariectomized.8 weeks later,the proximal one-third of the left tibia of all rats were inserted into self-drilling mini cortical screws.After operations,alendronate were used in group A and C and saline were given in group B and D.The rats were euthanized at 5 weeks after screws having been attached.Radiographic and histologic findings subsequently were analyzed.RESULTS :Radiographs confirmed that no osteolytic area was present around screws immediately after insertion,whereas 5 weeks after insertion,a wide and low-density area corresponding to the screw hole was evident in the saline groups compared with the alendronate groups.On histologic observation,the width of the fiber membrane and the number of TRAP-positive cells were decreased in the alendronate groups than those in the saline groups,and the difference was statistically significant.CONCLUSION :Alendronate effectly inhibits bone resorption of either normal or ovariectomized rats at the bone-screw interface in rats.
ABSTRACT
Serum tartrate-resistant acid phosphatase-5b (TRAP-5b) is a marker reflecting bone absorption. The results showed that serum TRAP-5b level was higher in postmenopausal than that in premenopausal normal women (P